Research
Hormonal
Specific blood lipid profiles (e.g., levels of triglycerides, lysophosphatidylcholine, and apolipoprotein E alleles) correlate with human aging and exceptional longevity.
Your blood lipid profile and ApoE genotype are markers of your biological aging and disease risk. While you cannot change your genotype, monitoring triglycerides and lysophosphatidylcholine levels may provide insights into your metabolic health. Focus on maintaining healthy lipid levels through diet and exercise.
ModerateQualifiesMEDIUM confidence
In humans, blood triglyceride levels tend to increase, while blood lysophosphatidylcholine levels tend to decrease with age. Specific sphingolipid and phospholipid blood profiles have also been shown to change with age and are associated with exceptional human longevity. For example, the epsilon 2 and epsilon 4 alleles of apolipoprotein E are associated with extreme longevity and late-onset neurodegenerative disease, respectively.
Why this rating
Observational data from genome-wide association studies and cohort studies.
Source
The role of lipid metabolism in aging, lifespan regulation, and age‐related disease
Adiv A. Johnson et al. · Aging Cell · 2019
DOI 10.1111/acel.13048
narrative_reviewCited 461×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Surgical removal of adipose tissue and specific genetic modifications (e.g., deletion of diacylglycerol acyltransferase 1) extend lifespan in rodents.Good
- Genetic or pharmacological interventions that impair lipid synthesis (specifically ceramide and sphingolipid pathways) or enhance lipid hydrolysis (lysosomal lipases) extend lifespan in model organisms including nematodes and fruit flies.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →